Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Castle

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
JAMA|October 7, 2004
Cervical cancer screening among women without a cervixPhilip Castle
The Queensland Nurse|June 5, 2015
Gallipoli nurses should be equally recognizedPhilip Castle
Obstetrics and Gynecology|June 24, 2009
Cervical cancers after human papillomavirus vaccinationPhilip Castle
Journal of the National Cancer Institute|August 3, 2013
RE: population-level impact of the bivalent, quadrivalent, and candidate nonavalent human papillomavirus vaccines: a comparative model-based analysisPhilip Castle
Women'S Health (London, England)|October 24, 2013
Current status and future trends in cervical cancer screeningPhilip Castle, Michael Dowdall
Journal of the National Cancer Institute|March 20, 2003
Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasiaMark H Schiffman, Philip Castle
Internal Medicine (Tokyo, Japan)|July 17, 2015
Human Papillomavirus (HPV) Vaccination: Just the FactsPhilip Castle, Ryo Konno, Xavier Bosch
Obstetrics and Gynecology|June 2, 2007
Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significanceMahboobeh Safaeian, Diane Solomon, Sholom Wacholder, et al.
BMJ (Clinical Research Ed.)|December 7, 2018
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analysesMarc Arbyn, Sara B Smith, Sarah Temin, et al.
Obstetrics and Gynecology|August 2, 2007
Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalitiesDiane Solomon, Mark Stoler, Jose Jeronimo, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
JAMA|October 7, 2004
Cervical cancer screening among women without a cervixPhilip Castle
The Queensland Nurse|June 5, 2015
Gallipoli nurses should be equally recognizedPhilip Castle
Obstetrics and Gynecology|June 24, 2009
Cervical cancers after human papillomavirus vaccinationPhilip Castle
Journal of the National Cancer Institute|August 3, 2013
RE: population-level impact of the bivalent, quadrivalent, and candidate nonavalent human papillomavirus vaccines: a comparative model-based analysisPhilip Castle
Women'S Health (London, England)|October 24, 2013
Current status and future trends in cervical cancer screeningPhilip Castle, Michael Dowdall
Journal of the National Cancer Institute|March 20, 2003
Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasiaMark H Schiffman, Philip Castle
Internal Medicine (Tokyo, Japan)|July 17, 2015
Human Papillomavirus (HPV) Vaccination: Just the FactsPhilip Castle, Ryo Konno, Xavier Bosch
Obstetrics and Gynecology|June 2, 2007
Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significanceMahboobeh Safaeian, Diane Solomon, Sholom Wacholder, et al.
BMJ (Clinical Research Ed.)|December 7, 2018
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analysesMarc Arbyn, Sara B Smith, Sarah Temin, et al.
Obstetrics and Gynecology|August 2, 2007
Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalitiesDiane Solomon, Mark Stoler, Jose Jeronimo, et al.
Pageof 2